Groupe la Francaise Grows Stake in DexCom, Inc. $DXCM

Groupe la Francaise lifted its position in DexCom, Inc. (NASDAQ:DXCM) by 88.6% during the 2nd quarter, HoldingsChannel reports. The firm owned 77,026 shares of the medical device company’s stock after buying an additional 36,180 shares during the period. Groupe la Francaise’s holdings in DexCom were worth $6,694,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the business. SWS Partners bought a new position in shares of DexCom in the second quarter worth approximately $1,661,000. Baader Bank Aktiengesellschaft purchased a new position in DexCom in the 2nd quarter worth approximately $393,000. Jennison Associates LLC increased its holdings in shares of DexCom by 9.4% in the 2nd quarter. Jennison Associates LLC now owns 11,517,546 shares of the medical device company’s stock worth $1,005,367,000 after buying an additional 994,300 shares during the last quarter. Assenagon Asset Management S.A. increased its holdings in shares of DexCom by 85.7% in the 2nd quarter. Assenagon Asset Management S.A. now owns 1,208,255 shares of the medical device company’s stock worth $105,469,000 after buying an additional 557,576 shares during the last quarter. Finally, Shell Asset Management Co. raised its position in shares of DexCom by 16.8% during the 2nd quarter. Shell Asset Management Co. now owns 35,812 shares of the medical device company’s stock valued at $3,126,000 after buying an additional 5,138 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

Insider Buying and Selling

In related news, Director Richard Alexander Collins sold 3,948 shares of the company’s stock in a transaction on Monday, November 10th. The shares were sold at an average price of $55.17, for a total transaction of $217,811.16. Following the completion of the sale, the director directly owned 37,994 shares in the company, valued at $2,096,128.98. This represents a 9.41% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Bridgette P. Heller sold 1,012 shares of the firm’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $58.07, for a total transaction of $58,766.84. Following the completion of the sale, the director directly owned 27,031 shares in the company, valued at approximately $1,569,690.17. This trade represents a 3.61% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 9,999 shares of company stock valued at $619,391 over the last quarter. Company insiders own 0.32% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. TD Cowen reduced their target price on DexCom from $100.00 to $84.00 and set a “buy” rating on the stock in a research note on Friday, October 31st. JPMorgan Chase & Co. reduced their price objective on DexCom from $90.00 to $75.00 and set a “neutral” rating on the stock in a research report on Friday, October 31st. Wells Fargo & Company set a $93.00 price objective on DexCom and gave the company an “overweight” rating in a report on Friday, October 31st. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of DexCom in a research note on Monday. Finally, Truist Financial reiterated a “buy” rating and set a $82.00 price target (down from $94.00) on shares of DexCom in a research report on Monday, November 3rd. Three investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, DexCom has a consensus rating of “Moderate Buy” and a consensus price target of $87.27.

DexCom Trading Up 1.5%

NASDAQ DXCM opened at $64.45 on Wednesday. The firm has a market cap of $25.14 billion, a PE ratio of 35.81, a price-to-earnings-growth ratio of 1.36 and a beta of 1.51. DexCom, Inc. has a 1-year low of $54.11 and a 1-year high of $93.25. The stock has a 50-day moving average of $64.12 and a 200-day moving average of $75.45. The company has a current ratio of 1.56, a quick ratio of 1.38 and a debt-to-equity ratio of 0.45.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, October 30th. The medical device company reported $0.61 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.04. DexCom had a return on equity of 30.65% and a net margin of 15.96%.The business had revenue of $1.21 billion for the quarter, compared to analysts’ expectations of $1.18 billion. During the same period in the previous year, the firm earned $0.45 EPS. The business’s quarterly revenue was up 21.6% on a year-over-year basis. As a group, sell-side analysts forecast that DexCom, Inc. will post 2.03 EPS for the current year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.